Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02154776 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
A Phase 1 study of Advanced or Metastatic Breast Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 6
- Study locations
NCT02154776 is a Phase 1 study of Advanced or Metastatic Breast Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 13 participants, below the 420-participant average among 3 other Advanced or Metastatic Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT02154776, a Phase 1 study of Advanced or Metastatic Breast Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, open-label, non-randomized, phase I study
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG LEE011
- DRUG Buparlisib
Study Locations (6)
California
- University of California at Los Angeles UCLA SC - Los Angeles
Indiana
- Horizon Oncology Center SC - Lafayette
South Carolina
- Medical University of South Carolina SC - Charleston
Texas
- South Texas Accelerated Research Therapeutics SC - San Antonio
Utah
- University of Utah / Huntsman Cancer Institute SC-3 - Salt Lake City
Other
- Novartis Investigative Site - Madrid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-06-27 |
| Est. Completion | 2016-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02154776
The ClinicalTrials.gov registry entry for NCT02154776 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 420-participant average among 3 other Advanced or Metastatic Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Letrozole is the first listed.
NCT02154776 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Indiana, South Carolina.
Frequently Asked Questions
What is clinical trial NCT02154776 about?
NCT02154776 is a clinical study titled "Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.". This is a multi-center, open-label, non-randomized, phase I study
What is the current status of trial NCT02154776?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2014-06-27. Estimated completion is 2016-10-26.
What conditions does trial NCT02154776 study?
This clinical trial studies the following conditions: Advanced or Metastatic Breast Cancer.
What interventions are being tested in trial NCT02154776?
The interventions under investigation include: Letrozole (DRUG), LEE011 (DRUG), Buparlisib (DRUG).
Who is sponsoring clinical trial NCT02154776?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02154776 being conducted?
This trial has 6 study locations across California, Indiana, South Carolina, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
RECRUITING · Phase 1
-
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.